At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
MK-1075drug
Likely dose
MK-1075 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Rising Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-1075 in HCV-Infected Patients
In Brief
A Phase 1 clinical trial evaluating MK-1075 for Hepatitis C. Completed, enrolled 9 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionAug 2015
TodayJul 2026
First PostedMar 19, 2015
Enrollment StartApr 28, 2015
Primary CompletionAug 10, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.3 years ago
Interventions
MK-1075drug
MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.